Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066623 | 0.89 | RAB9A (0.42) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5066622 | 0.89 | RAB9A (0.42) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14319934 | 0.83 | ALDH1A1 (0.46) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5068238 | 0.82 | NPC1 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5694430 | 0.77 | NPC1 (0.56) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5068704 | 0.77 | ALDH1A1 (0.47) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL5066571 | 0.77 | KMT2A (0.64) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5069111 | 0.75 | MRGPRX4 (0.44) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27503015 | 0.74 | MAPT (0.41) | MAPTL3MBTL1ERN1PTGER1MRGPRX4 | |
| SCHEMBL5694412 | 0.73 | KMT2A (0.59) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653947-B1 | (4-HYDROXYPHENYL)-1H-INDOLE-3-CARBALDEHYDE OXIME DERIVATIVES AS ESTROGENIC AGENTS | WYETH CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070249703-A1 | (Hydroxyphenyl)-1H-Indole-3-Carbaldehyde Oxime Derivatives As Estrogenic Agents | WYETH (US) | 2007-10-25 | — | — | US | disclosed |
| US-7250440-B2 | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents | WYETH (US) | 2007-07-31 | — | — | US | disclosed |
| CN-1867329-A | (4-hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivative as estrogenic agents | WYETH CORP (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1653947-A1 | (4-HYDROXYPHENYL)-1H-INDOLE-3-CARBALDEHYDE OXIME DERIVATIVES AS ESTROGENIC AGENTS | Wyeth Holdings Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050059723-A1 | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005018636-A1 | (4-HYDROXYPHENYL)-1H-INDOLE-3-CARBALDEHYDE OXIME DERIVATIVE AS ESTROGENIC AGENTS | WYETH (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249703-A1 | (Hydroxyphenyl)-1H-Indole-3-Carbaldehyde Oxime Derivatives As Estrogenic Agents | ESR1, ESR2, GPER1 | MEN1 2305/4885KMT2A 538/4885NPC1 4052/4885 |
| US-20050059723-A1 | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents | ESR1, ESR2, GPER1 | MEN1 2305/4885KMT2A 538/4885NPC1 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.